4.2 Review

Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools

Journal

PHARMACEUTICAL STATISTICS
Volume 20, Issue 1, Pages 185-195

Publisher

WILEY
DOI: 10.1002/pst.2068

Keywords

AMSTAR2; AMSTAR-PLUS; Cochrane; CONSORT; meta-analysis; meta-research; NOS; PRISMA; quality; STROBE

Ask authors/readers for more resources

Systematic reviews and meta-analyses are crucial in providing higher level evidence for healthcare decisions by pooling data from individual studies. The quality of evidence synthesis depends on the quality of studies included and the methodologically correct process of systematic reviews and meta-analyses. Different tools, such as NOS, STROBE, CONSORT, Jadad scale, RoB2, PRISMA, AMSTAR2, and AMSTAR-PLUS, are commonly used to assess the quality of studies and reviews.
Systematic reviews and meta-analyses pool data from individual studies to generate a higher level of evidence to be evaluated by guidelines. These reviews ultimately guide clinicians and stakeholders in health-related decisions. However, the informativeness and quality of evidence synthesis inherently depend on the quality of what has been pooled into meta-research projects. Moreover, beyond the quality of included individual studies, only a methodologically correct process, in relation to systematic reviews and meta-analyses themselves, can produce a reliable and valid evidence synthesis. Hence, quality of meta-research projects also affects evidence synthesis reliability. In this overview, the authors provide a synthesis of advantages and disadvantages and main characteristics of some of the most frequently used tools to assess quality of individual studies, systematic reviews, and meta-analyses. Specifically, the tools considered in this work are the Newcastle-Ottawa scale (NOS) and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) for observational studies, the Consolidated Standards of Reporting Trials (CONSORT), the Jadad scale, the Cochrane risk of bias tool 2 (RoB2) for randomized controlled trials, the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and the Assessment of Multiple Systematic Reviews 2 (AMSTAR2), and AMSTAR-PLUS for meta-analyses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available